Placebo plus metformin — Competitive Intelligence Brief

Placebo plus metformin (Placebo plus metformin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

marketed Biguanide AMP-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule

Target snapshot

Placebo plus metformin (Placebo plus metformin) — University Magna Graecia. Metformin reduces hepatic glucose production and improves insulin sensitivity, while the placebo control arm receives no active pharmacological intervention.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo plus metformin TARGET	Placebo plus metformin	University Magna Graecia	marketed	Biguanide	AMP-activated protein kinase (AMPK), mitochondrial glycerophosphate dehydrogenase
rosiglitazone maleate/metformin hydrochloride	rosiglitazone maleate/metformin hydrochloride	GlaxoSmithKline	marketed	Thiazolidinedione/Biguanide combination	PPAR-γ (rosiglitazone); Complex I of mitochondrial respiratory chain (metformin)
rosiglitazone-metformin	rosiglitazone-metformin	GlaxoSmithKline	marketed	Thiazolidinedione + Biguanide combination	PPAR-γ (rosiglitazone component); Complex mitochondrial mechanism (metformin component)
Saxagliptin + Metformin	Saxagliptin + Metformin	AstraZeneca	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I and AMPK
Insulin glargine combined with metformin	Insulin glargine combined with metformin	Sun Yat-sen University	marketed	Insulin + biguanide combination	Insulin receptor (insulin glargine); AMP-activated protein kinase and mitochondrial complex I (metformin)
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
Sitagliptin + Metformin	Sitagliptin + Metformin	Baylor College of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

1. AstraZeneca · 4 drugs in this class
2. Merck Sharp & Dohme LLC · 3 drugs in this class
3. University of Texas Southwestern Medical Center · 2 drugs in this class
4. Mount Sinai Hospital, Canada · 2 drugs in this class
5. GlaxoSmithKline · 2 drugs in this class
6. Eli Lilly and Company · 2 drugs in this class
7. University Magna Graecia · 2 drugs in this class
8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class